Why the study?
The true incidence of pericardial effusion with minoxidil has been difficult to estimate because initial descriptions involved patients with severe hypertension and chronic renal or cardiac failure.
Does low-dose oral minoxidil cause pericardial effusion or other cardiovascular side effects in patients with hair loss?
Does low-dose oral minoxidil cause pericardial effusion or other cardiovascular side effects in patients with hair loss?
Low-dose oral minoxidil for hair loss appears safe from a cardiovascular perspective, with no observed cases of pericardial effusion, syncope, or tachycardia in a large cohort.
Answers are grounded in this paper and cite their sources.
Supports cautious off-label oral minoxidil exploration in alopecia; leaves open dosing, efficacy, and safety in RCTs.
Sir, Minoxidil is a potent antihypertensive vasodilator, first approved by the Food and Drug Administration (FDA) in the United States in 1979 for the treatment of hypertension.[1] Minoxidil acts as an antihypertensive agent by opening adenosine triphosphate-sensitive potassium channels in vascular smooth muscle. The predominant site of minoxidil action is arterial. Venodilatation does not occur with minoxidil; thus, postural hypotension is unusual with its administration.[2] The arteriolar vasodilation brought about by minoxidil can stimulate the peripheral sympathetic nervous system (SNS) by the way of carotid and aortic baroreceptor reflexes.[3] In conjunction with activation of the SNS, both pulse rate and cardiac output increase with minoxidil; however, cardiac output and heart rate will tend to revert to pretreatment values with long-term treatment.[4] Minoxidil administration also brings about an increase in plasma renin activity, largely due to the aforementioned activation of the SNS.[1,5] This activation of the renin-angiotensin axis further prompts increased biosynthesis of aldosterone; whereas plasma and urinary aldosterone levels are increased early in the course of treatment with minoxidil, over time these values tend to normalize presumably because of accelerated metabolic clearance of aldosterone in association with hepatic vasodilation.[6] Although minoxidil is effective in reducing blood pressure (BP), the counterregulatory hemodynamic changes that accompany its use can offset the BP-lowering effect that ensues from arteriolar vasodilatation. Minoxidil is completely and rapidly absorbed from the gastrointestinal tract.[1] Minoxidil is a prodrug, metabolized hepatically to an active metabolite, minoxidil sulfate which is then cleared renally. Minoxidil is minimally protein bound. The plasma half-life of minoxidil is 3-4 h; however, the duration of its hypotensive effect can endure for 72 h, which supports its once-daily dosing.[7] In 1980, Zapacosta reported the reversal of baldness in a patient receiving minoxidil for hypertension.[8] In 1988, the FDA approval minoxidil 2% lotion for the treatment of androgenetic alopecia in males, and in 1992, the 2% minoxidil lotion was also approved for use in females. In 1997, the FDA approved 5% extra strength minoxidil lotion.[9] Following oral ingestion of minoxidil, serum levels of >21.7 ng/ml are required for minor hemodynamic changes. Following topical application of minoxidil lotion to the scalp, mean serum levels posttreatment (CMAX) were 1.8 ng/ml for 5% group and 0.7 ng/ml for 2% minoxidil group. The maximum level reported following topical application was 18.2 ng/ml. Fluctuating changes in BP and pulse rate following topical application of minoxidil are considered physiological.[10,11] Oral minoxidil is currently used for the management of severe hypertension associated with target organ damage in patients who have failed to respond to maximum doses of a diuretic plus 2 other antihypertensive drugs.[4] For adults and children older than 12 years, minoxidil is commenced at a starting dose of 5 mg/day. And if necessary, the dose can be increase to 10, 20, and then 40 mg/day in single or divided doses up to a maximum dose of 100 mg/day). Reported cardiovascular side effects include: Asymptomatic electrocardiography (ECG) changes (60%);[12] pericardial effusion leading to tamponade (3%);[13] BP changes, chest pain, and tachycardia. Sudden weight gain and temporary edema have been reported (7%) along with elevation in serum creatinine (7%). Fluid retention and tachycardia are dose-dependent side effects that occur with minoxidil.[1,11] The mechanism of the sodium and water retention with minoxidil is a varying combination of renal hemodynamic, and/or neurohumoral changes as well as direct tubular effects. The latter may relate to minoxidil’s action as a potassium channel opener. The true incidence of pericardial effusion with minoxidil is difficult to estimate because many patients in the initial descriptions have chronic cardiac and renal failure that are known risks for pericardial effusions and there was no pretreatment echocardiogram. Almost all cases of pericardial effusion were reported in patients who were severely hypertensive with coexistent renal or cardiac impairment. Most effusions resolved with continued treatment with minoxidil.[12] Among patients on dialysis who received minoxidil, the incidence of pericardial disorders did not differ from those reported in other dialysis populations not treated with minoxidil.[13] In the nondialysis group, pericardial disorders were attributed to associated systemic disorders such as lupus erythematosus or chronic cardiac failure[14] Dermatologic side effects include hypertrichosis (80%, 24%–100%) and 1 case of Stevens-Johnson syndrome and 1 case of TEN. Over a 10-year period between 2005 and 2015, we treated 3747 distinct patients with hair loss with oral minoxidil in doses ranging from 0.1 mg daily to 20 mg daily [Table 1]. All patients have now been followed up for a minimum of 5 years (range 5–15 years). There were 989 men and 2736 women. Patients were generally commenced on a low dose and reviewed at 3-month intervals. When necessary, doses were escalated. In the men, minoxidil was used either alone as monotherapy (62) or together with finasteride (912) or dutasteride.Table 1: Maximum oral daily dose of minoxidil among 3747 patientsFifty-five men received doses equal to or >10 mg. There were no cases of syncope, tachycardia, or pericardial effusion identified among these men. Thirty-six of these asymptomatic men were investigated with an ECG. All ECGs were reported as normal. There were no cases where echocardiography was clinically indicated. Among the women, 2793 received doses between 0.1 mg and 5 mg. In the women, minoxidil was used either alone as monotherapy (805) or together with spironolactone (1285), cyproterone acetate (630) of flutamide (68), or bicalutamide (5). There were no cases of syncope, tachycardia, or pericardial effusion identified among these women. There were no patients where further investigations with ECG or echocardiography were clinically indicated. Low-dose oral minoxidil is well tolerated from a cardiovascular perspective. The risk of pericardial effusion is dose related. A review of the literature reveals that all cases have been associated with hypertension and that most cases are associated with additional renal or cardiac failure. There are no reports of pericardial effusion with topical minoxidil after 25 years of widespread usage. The lowest dose of minoxidil previously reports to be associated with pericardial effusion is 5 mg. Most reports are associated with doses >20 mg. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Rodney Sinclair (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: